ParinGenix, Inc., a clinical-stage pharmaceutical company, develops 2-O and 3-O desulfated heparin to ameliorate cardiac ischemia-reperfusion injury. It provides PGX-100, which reduces damage to the heart in animal models of myocardial infarction. ParinGenix, Inc. was incorporated in 2002 and is based in Weston, Florida.